Bloomage Biotech(SH:688363) Zhi Tong Cai Jing·2025-09-08 05:52Core Viewpoint - Sainteno Pharmaceuticals-B (02257) has seen its stock price increase by over 90% in the month, with a current rise of 18.84% to HKD 17.79, and a trading volume of HKD 45.3042 million [1] Group 1: Fundraising and Stock Performance - Sainteno Pharmaceuticals announced a plan to issue 17.3524 million subscription shares to Huaxi Biotechnology (Hong Kong) Co., Ltd. and two other parties at HKD 12.00 per share, representing a discount of approximately 19.84% compared to the closing price of HKD 14.97 on September 5 [1] - The fundraising is expected to net approximately HKD 206 million, which will be used for general operating funds [1] Group 2: Product Development and Clinical Trials - STP705 is the fastest progressing product in Sainteno's pipeline, anticipated to become the company's first commercialized product by 2025 [1] - STP705 targets both TGF-β1 and COX-2 as a dual-target siRNA and is the first and only drug in the siRNA cancer treatment field to achieve positive Phase II clinical results [1] - In the Phase II clinical trial for treating basal cell carcinoma, the 180ug dosage group achieved a 100% complete clearance rate [1] - The company is expanding STP705's indications, having initiated Phase II clinical trials for scars, Phase I clinical trials for adult abdominal liposuction, and Phase I clinical trials for liver cancer [1] - STP705 has also received orphan drug designation for the treatment of cholangiocarcinoma and primary sclerosing cholangitis [1]